Farallon Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Farallon Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$360K	Hold	4,800	–	–	﹤0.01%	111
2025 Q4	$380K	Hold	4,800	–	–	﹤0.01%	100
2025 Q3	$314K	Buy	+4,800	New	+$234K	﹤0.01%	102
2024 Q3	–	Sell	-4,800	Closed	-$229K	–	170
2024 Q2	$229K	Sell	4,800 -729,200	-99%	-$29.9M	﹤0.01%	129
2024 Q1	$31.8M	Sell	734,000 -821,020	-53%	-$39.1M	0.14%	63
2023 Q4	$78.7M	Buy	1,555,020 +828,020	+114%	+$39.7M	0.36%	51
2023 Q3	$33M	Buy	727,000 +722,000	+14,440%	+$29.8M	0.15%	69
2023 Q2	$205K	Buy	+5,000	New	+$192K	﹤0.01%	137
2021 Q2	–	Sell	-630,500	Closed	-$28.3M	–	308
2021 Q1	$28.3M	Sell	630,500 -119,500	-16%	-$6.66M	0.14%	90
2020 Q4	$42.4M	Buy	+750,000	New	+$37.4M	0.26%	70
2018 Q1	–	Sell	-645,000	Closed	-$32.4M	–	96
2017 Q4	$32.4M	Buy	645,000 +195,000	+43%	+$10.7M	0.26%	49
2017 Q3	$22.8M	Buy	+450,000	New	+$23.6M	0.2%	53

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Farallon Capital Management's IONS Position: Q1 2026 in Review

Farallon Capital Management held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 4,800 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #111.

Farallon Capital Management first reported a position in IONS in Q3 2017 and has held it in 12 quarters since. The position peaked at $78.7M in Q4 2023. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Farallon Capital Management held 4,800 shares of Ionis Pharmaceuticals worth $360K as of Q1 2026.
Farallon Capital Management left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #111 holding.
Farallon Capital Management first reported a position in Ionis Pharmaceuticals in Q3 2017 and has held it in 12 quarters since.
Farallon Capital Management's Ionis Pharmaceuticals position peaked at $78.7M in Q4 2023.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.